ESMO 2021 | Clinical implications of the PRISM in RCC

Naveen S. Vasudev, BMSc (Hons), MBCHB, MRCP, PhD, The University of Leeds, Leeds, UK, discusses the clinical implications of the PRISM study, which showed that a modified schedule of 4 doses of 12-weekly ipilimumab decreased the rates of grade 3-4 treatment-related toxicities in comparison to the standard schedule of 4 doses of 3-weekly ipilimumab, whilst maintaining treatment efficacy in patients with renal cell carcinoma (RCC). These results highlight that the optimal delivery of these drugs needs to be further investigated and that dosing delay is a viable option for patients that require it. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.